NCT03798964

Completed

The Expression Heparanase in Term and Preterm Placentas

Hillel Yaffe Medical Center Source

Compare

Other study identifiers

Sponsor study identifier

HYMC-0119-18

Study Type

observational

Actual enrollment (reported)

20

Locations

1 country

Sites

1

Timeline

Study Start

January 23, 2019

Actual (reported)

Primary Completion

November 24, 2020

Actual (reported)

Study Completion

November 24, 2020

Actual (reported)

Brief Summary

Heparanase is an endo-β-glucuronidase that cleaves heparin-sulfate (HS) side chains of heparan sulfate proteoglycans, an integral constituent of the extra cellular matrix (ECM). This study aims to investigate the association between heparanase expression in the human placenta and preterm birth (PTB) . The investigators hypothesize that an abnormal placentation causes relative placental ischemia that induces higher rates of heparanase expression.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 20 participants
Study completion date: November 24, 2020
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Some registry-reported names shown below are not yet linked in this graph.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

First Submitted
January 2, 2019
Actual (reported)
First Posted
January 10, 2019
Actual (reported)
Study Start
January 23, 2019
Actual (reported)
Primary Completion
November 24, 2020
Actual (reported)
Study Completion
November 24, 2020
Actual (reported)

Last Updated: June 28, 2022
Status Verified: June 2022
Last Update Submitted: June 22, 2022

Conditions

Preterm Birth

Outcome Measures

Primary Outcomes (1)

Heparanase expression
Heparanase expression in the human placenta following delivery will be evaluated by western blot analysis in the three groups and will be compared to determine differences in the levels.
Six months

Study Arms (3)

Elective term cesarean

Low-risk women undergoing elective term cesarean section

Other: Placental analysis

Term vaginal delivery

Low-risk women undergoing term vaginal delivery

Other: Placental analysis

Preterm vaginal delivery

Women undergoing preterm vaginal delivery

Other: Placental analysis

Interventions

Placental analysisOther

Analysis of placenta to determine expression of heparanase

Elective term cesareanPreterm vaginal deliveryTerm vaginal delivery

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 40 Years

Sexfemale(Gender-based eligibility)

Healthy VolunteersNo

Age GroupsAdult (18-64)

Sampling MethodNon-Probability Sample

Study Population

Pregnant women attending our obstetrical unit

You may qualify if:

Singleton pregnancy

You may not qualify if:

Sponsors & Collaborators

Hillel Yaffe Medical Center
Governmentlead

Study Sites (1)

Hille Yaffe Medical Center

Hadera, 38100, Israel

MeSH Terms

Conditions

Premature Birth

Condition Hierarchy (Ancestors)

Obstetric Labor, PrematureObstetric Labor ComplicationsPregnancy ComplicationsFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital Diseases

Study Officials

Rinat Gabbay-Benziv, MD
Hillel Yaffe Medical Center
PRINCIPAL INVESTIGATOR

Enrollment

20 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: COHORT
Time Perspective: PROSPECTIVE
Sponsor Type: OTHER GOV
Responsible Party: SPONSOR

Study Record Dates

First Submitted

January 2, 2019

First Posted

January 10, 2019

Study Start

January 23, 2019

Actual (reported)

NCT03530332

Prediction and Prevention of Preterm Birth (PREVENT-PTB Study)

Not ApplicableTerminated

NCT04008485

Clinical Grade MIS Device for Cervical Assessment to Predict Preterm Birth

Not ApplicableCompleted

NCT05698836

Cardiovascular Health Assessment of Preterm- and TERm-born Children

Enrolling By Invitation

NCT03589365

Preterm Birth and Long Term Consequences on Myocardial Functions and Structure

Not ApplicableUnknown

NCT03564184

Longitudinal Study of Music Therapy's Effectiveness for Premature Infants and Their Caregivers

Not ApplicableCompleted

NCT02928302

Transvaginal Ultrasound Cervical Length Screening in Singleton Pregnancy Without Prior Spontaneous Preterm Birth

Phase 3Withdrawn

High-risk patients
Multiple pregnancy
Significant maternal illness
Significant fetal anomaly

Contact the study team to confirm eligibility.

Primary Completion

November 24, 2020

Actual (reported)

Study Completion

November 24, 2020

Actual (reported)

Last Updated

June 28, 2022

Record last verified: 2022-06

Data Sharing

IPD Sharing: Will not share

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT03798964
Data provider: ClinicalTrials.gov
Source updated: 2022-06-28
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:36:14 UTC

Locations

IL(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (3)

Elective term cesarean

Term vaginal delivery

Preterm vaginal delivery

Interventions

Eligibility Criteria

You may qualify if:

You may not qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Data Sharing

Source record

Locations